JP2021534185A5 - - Google Patents
Info
- Publication number
- JP2021534185A5 JP2021534185A5 JP2021507918A JP2021507918A JP2021534185A5 JP 2021534185 A5 JP2021534185 A5 JP 2021534185A5 JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021534185 A5 JP2021534185 A5 JP 2021534185A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- statin
- approximately
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719404P | 2018-08-17 | 2018-08-17 | |
| US62/719,404 | 2018-08-17 | ||
| PCT/US2019/046710 WO2020037153A1 (en) | 2018-08-17 | 2019-08-15 | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534185A JP2021534185A (ja) | 2021-12-09 |
| JP2021534185A5 true JP2021534185A5 (https=) | 2022-08-22 |
| JPWO2020037153A5 JPWO2020037153A5 (https=) | 2022-08-22 |
Family
ID=69524891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507918A Pending JP2021534185A (ja) | 2018-08-17 | 2019-08-15 | スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220362200A1 (https=) |
| EP (1) | EP3836914A4 (https=) |
| JP (1) | JP2021534185A (https=) |
| KR (1) | KR20210047312A (https=) |
| CN (1) | CN112912071A (https=) |
| AU (2) | AU2019321568B2 (https=) |
| BR (1) | BR112021002884A2 (https=) |
| CL (3) | CL2021000400A1 (https=) |
| EA (1) | EA202190547A1 (https=) |
| IL (1) | IL280643A (https=) |
| MA (1) | MA52680A1 (https=) |
| MX (1) | MX2021001906A (https=) |
| NI (1) | NI202100009A (https=) |
| PH (1) | PH12021550328A1 (https=) |
| SG (1) | SG11202101562UA (https=) |
| TN (1) | TN2021000028A1 (https=) |
| WO (1) | WO2020037153A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SG10201605794PA (en) | 2009-04-29 | 2016-09-29 | Amarin Pharmaceuticals Ie Ltd | Stable Pharmaceutical Composition And Methods Of Using Same |
| EP3318255B1 (en) | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| AU2010298222B2 (en) | 2009-09-23 | 2017-01-05 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| NZ727849A (en) | 2012-06-29 | 2018-06-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US12430998B2 (en) | 2018-09-14 | 2025-09-30 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| US11645899B2 (en) | 2018-09-14 | 2023-05-09 | Avive Solutions, Inc. | Responder network |
| US11640755B2 (en) | 2018-09-14 | 2023-05-02 | Avive Solutions, Inc. | Real time defibrillator incident data |
| LT3750536T (lt) | 2018-09-24 | 2026-03-25 | Amarin Pharmaceuticals Ireland Limited | Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| WO2021102246A1 (en) * | 2019-11-21 | 2021-05-27 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CA3217098A1 (en) * | 2021-04-29 | 2022-11-03 | Richard Louis Dunbar | Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090239927A1 (en) * | 2004-12-06 | 2009-09-24 | George Bobotas | Statin and Omega-3 Fatty Acids For Lipid Therapy |
| JP2009544701A (ja) * | 2006-07-21 | 2009-12-17 | リライアント・ファーマシューティカルズ・インコーポレイテッド | オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 |
| NZ727849A (en) * | 2012-06-29 | 2018-06-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20140322314A1 (en) * | 2013-04-29 | 2014-10-30 | Matinas Biopharma, Inc. | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment |
| AU2015231713B2 (en) * | 2014-03-17 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Methods for reducing cardiovascular risk |
| US10406130B2 (en) * | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| DK3275438T3 (da) * | 2016-07-29 | 2021-01-18 | Kowa Co | Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko |
-
2019
- 2019-08-15 CN CN201980069084.5A patent/CN112912071A/zh active Pending
- 2019-08-15 MA MA52680A patent/MA52680A1/fr unknown
- 2019-08-15 EP EP19849946.9A patent/EP3836914A4/en active Pending
- 2019-08-15 SG SG11202101562UA patent/SG11202101562UA/en unknown
- 2019-08-15 WO PCT/US2019/046710 patent/WO2020037153A1/en not_active Ceased
- 2019-08-15 MX MX2021001906A patent/MX2021001906A/es unknown
- 2019-08-15 KR KR1020217007524A patent/KR20210047312A/ko not_active Ceased
- 2019-08-15 BR BR112021002884-6A patent/BR112021002884A2/pt not_active Application Discontinuation
- 2019-08-15 TN TNP/2021/000028A patent/TN2021000028A1/en unknown
- 2019-08-15 US US17/275,576 patent/US20220362200A1/en not_active Abandoned
- 2019-08-15 JP JP2021507918A patent/JP2021534185A/ja active Pending
- 2019-08-15 AU AU2019321568A patent/AU2019321568B2/en active Active
- 2019-08-15 EA EA202190547A patent/EA202190547A1/ru unknown
-
2021
- 2021-02-04 IL IL280643A patent/IL280643A/en unknown
- 2021-02-16 PH PH12021550328A patent/PH12021550328A1/en unknown
- 2021-02-16 NI NI202100009A patent/NI202100009A/es unknown
- 2021-02-16 CL CL2021000400A patent/CL2021000400A1/es unknown
- 2021-12-03 CL CL2021003222A patent/CL2021003222A1/es unknown
- 2021-12-03 CL CL2021003221A patent/CL2021003221A1/es unknown
-
2024
- 2024-08-21 US US18/810,687 patent/US20250186386A1/en active Pending
-
2025
- 2025-04-22 AU AU2025202801A patent/AU2025202801A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534185A5 (https=) | ||
| JPWO2020037153A5 (https=) | ||
| US11179362B2 (en) | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | |
| JP2020128412A5 (https=) | ||
| US20220323395A1 (en) | Methods of treating hypertriglyceridemia | |
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| JP6419927B2 (ja) | 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法 | |
| US10966951B2 (en) | Compositions and methods for lowering triglycerides in a subject having reduced kidney function | |
| ES2769926T3 (es) | Ester etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia | |
| US20200108041A1 (en) | Methods of reducing ldl-p | |
| US20140221676A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| US20150250757A1 (en) | Methods for treating hypertriglyceridemia | |
| US20140004183A1 (en) | Methods for treating cardiovascular disease in statin-tolerant subjects | |
| Nissen | When is a placebo not a placebo | |
| ES2524596T3 (es) | Tratamiento a largo plazo de la insuficiencia cardiaca sintomática | |
| Savelieva et al. | Polyunsaturated fatty acids for prevention of atrial fibrillation: a ‘fishy'story | |
| HK40036364A (en) | Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy | |
| Mihaiu et al. | Experimental Studies on Guinea Pig Regarding the Influence of Polyunsaturated Fatty Acids as Enhancer in Statin Medication | |
| HK1255106B (en) | Compositions and methods for treating stroke in a subject on concomitant statin therapy | |
| AU2016231552A1 (en) | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia | |
| HK1169838B (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| HK1169838A (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| HK1203764B (en) | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |